Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139


Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma.

Zhou Z, Guan H, Duan X, Kleinerman ES.

Cancer. 2005 Oct 15;104(8):1713-20.


Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.

Lu S, Zhang J, Zhou Z, Liao ML, He WZ, Zhou XY, Li ZM, Xiang JQ, Wang JJ, Chen HQ.

Oncol Rep. 2008 Sep;20(3):581-7.


Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.

Ottewell PD, Deux B, Mönkkönen H, Cross S, Coleman RE, Clezardin P, Holen I.

Clin Cancer Res. 2008 Jul 15;14(14):4658-66. doi: 10.1158/1078-0432.CCR-07-1545.


The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.

Peng H, Sohara Y, Moats RA, Nelson MD Jr, Groshen SG, Ye W, Reynolds CP, DeClerck YA.

Cancer Res. 2007 Oct 1;67(19):9346-55.


Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing's sarcoma via inhibition of cell migration.

Odri G, Kim PP, Lamoureux F, Charrier C, Battaglia S, Amiaud J, Heymann D, Gouin F, Redini F.

BMC Cancer. 2014 Mar 10;14:169. doi: 10.1186/1471-2407-14-169.


Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms.

Quinn JE, Brown LG, Zhang J, Keller ET, Vessella RL, Corey E.

Prostate Cancer Prostatic Dis. 2005;8(3):253-9.


In vitro antitumor effect of sodium butyrate and zoledronic acid combined with traditional chemotherapeutic drugs: a paradigm of synergistic molecular targeting in the treatment of Ewing sarcoma.

Dos Santos MP, de Farias CB, Roesler R, Brunetto AL, Abujamra AL.

Oncol Rep. 2014 Feb;31(2):955-68. doi: 10.3892/or.2013.2907. Epub 2013 Dec 6.


Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone.

Ottewell PD, Woodward JK, Lefley DV, Evans CA, Coleman RE, Holen I.

Mol Cancer Ther. 2009 Oct;8(10):2821-32. doi: 10.1158/1535-7163.MCT-09-0462. Epub 2009 Sep 29.


Death receptor 5 agonist TRA8 in combination with the bisphosphonate zoledronic acid attenuated the growth of breast cancer metastasis.

Szafran AA, Folks K, Warram J, Chanda D, Wang D, Zinn KR.

Cancer Biol Ther. 2009 Jun;8(12):1109-16.


Nicotine and lipopolysaccharide stimulate the formation of osteoclast-like cells by increasing macrophage colony-stimulating factor and prostaglandin E2 production by osteoblasts.

Tanaka H, Tanabe N, Shoji M, Suzuki N, Katono T, Sato S, Motohashi M, Maeno M.

Life Sci. 2006 Mar 6;78(15):1733-40. Epub 2005 Nov 2.


Intensification therapy with anti-parathyroid hormone-related protein antibody plus zoledronic acid for bone metastases of small cell lung cancer cells in severe combined immunodeficient mice.

Yamada T, Muguruma H, Yano S, Ikuta K, Ogino H, Kakiuchi S, Hanibuchi M, Uehara H, Nishioka Y, Sone S.

Mol Cancer Ther. 2009 Jan;8(1):119-26. doi: 10.1158/1535-7163.MCT-08-0874.


Effect of combination therapy with a novel bisphosphonate, minodronate (YM529), and docetaxel on a model of bone metastasis by human transitional cell carcinoma.

Inoue K, Karashima T, Fukata S, Nomura A, Kawada C, Kurabayashi A, Furihata M, Ohtsuki Y, Shuin T.

Clin Cancer Res. 2005 Sep 15;11(18):6669-77.


Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis.

Haider MT, Holen I, Dear TN, Hunter K, Brown HK.

Bone. 2014 Sep;66:240-50. doi: 10.1016/j.bone.2014.06.023. Epub 2014 Jun 24.


Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.

Cao JJ, Wronski TJ, Iwaniec U, Phleger L, Kurimoto P, Boudignon B, Halloran BP.

J Bone Miner Res. 2005 Sep;20(9):1659-68. Epub 2005 May 2.


Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.

Ottewell PD, Mönkkönen H, Jones M, Lefley DV, Coleman RE, Holen I.

J Natl Cancer Inst. 2008 Aug 20;100(16):1167-78. doi: 10.1093/jnci/djn240. Epub 2008 Aug 11.


Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival.

Picarda G, Lamoureux F, Geffroy L, Delepine P, Montier T, Laud K, Tirode F, Delattre O, Heymann D, Rédini F.

Clin Cancer Res. 2010 Apr 15;16(8):2363-74. doi: 10.1158/1078-0432.CCR-09-1779. Epub 2010 Apr 6.


Effect of YM529 on a model of mandibular invasion by oral squamous cell carcinoma in mice.

Cui N, Nomura T, Noma H, Yokoo K, Takagi R, Hashimoto S, Okamoto M, Sato M, Yu G, Guo C, Shibahala T.

Clin Cancer Res. 2005 Apr 1;11(7):2713-9.


Zoledronic acid reduces bone loss and tumor growth in an orthotopic xenograft model of osteolytic oral squamous cell carcinoma.

Martin CK, Werbeck JL, Thudi NK, Lanigan LG, Wolfe TD, Toribio RE, Rosol TJ.

Cancer Res. 2010 Nov 1;70(21):8607-16. doi: 10.1158/0008-5472.CAN-10-0850. Epub 2010 Oct 19.


The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice.

Tannehill-Gregg SH, Levine AL, Nadella MV, Iguchi H, Rosol TJ.

Clin Exp Metastasis. 2006;23(1):19-31. Epub 2006 May 20.


Supplemental Content

Support Center